1.2 Sponsor & Investigator Responsibilities and Delegation of Authority
Key Takeaways
- The Sponsor is legally and operationally responsible for study design, financing, QA/QC systems, investigational product supply, monitoring, and safety reporting under ICH E6(R3) Annex 1 section 3 and 21 CFR 312.
- The Principal Investigator (PI) is directly responsible for site conduct, participant medical care, informed consent, protocol adherence, and investigational product accountability under ICH E6(R3) Annex 1 section 2 and Form FDA 1572.
- While a Sponsor may transfer operational functions to a Contract Research Organization (CRO), the ultimate legal responsibility for data quality and trial integrity always remains with the Sponsor.
- Investigators are legally bound by Form FDA 1572 commitments in US IND studies, including the pledge to personally conduct or supervise the trial and report all adverse events.
- Protocol amendments cannot be implemented without prior IRB/IEC approval except when immediately necessary to eliminate an apparent hazard to trial participants.
Sponsor & Investigator Responsibilities and Delegation of Authority
Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Annex 1 section 2 (Investigator) and section 3 (Sponsor), with Principle 10 on retained responsibility after transfer or delegation.
Core Principle: In clinical trials, regulatory bodies establish a strict division of responsibilities between the Sponsor (the entity that initiates, manages, and finances the trial) and the Investigator (the individual responsible for the actual conduct of the trial at the investigational site). Clear delineation of these roles prevents conflicts of interest, guarantees independent safety oversight, and safeguards data integrity.
1. Sponsor Responsibilities (ICH E6(R3) Annex 1 section 3 & 21 CFR 312 Subpart D)
The sponsor holds comprehensive responsibility for the overall trial lifecycle from conception to regulatory submission. Even when a sponsor engages specialized service providers, the sponsor retains ultimate accountability.
┌───────────────────────────────────────────────────────────────────────────┐
│ MAJOR SPONSOR RESPONSIBILITIES │
├───────────────────────────────────────────────────────────────────────────┤
│ • Trial Design & Protocol Development (scientifically sound, validated) │
│ • Quality Assurance (QA) & Quality Control (QC) Systems (written SOPs) │
│ • Securing Financing & Clinical Trial Agreements (CTA) │
│ • Selection of Qualified Investigators & Sites (verifying resources) │
│ • Collecting Financial Disclosures (21 CFR Part 54) │
│ • Regulatory Submissions (IND / CTA filings & annual reports) │
│ • Investigational Product (IP) Supply, Labeling, Blinding & Stability │
│ • Trial Monitoring (Risk-Based Monitoring plan, CRA oversight) │
│ • Expedited Safety Reporting (SUSARs to FDA, EMA, IRBs, Investigators) │
│ • Electronic Systems Validation & Data Management (21 CFR Part 11) │
└───────────────────────────────────────────────────────────────────────────┘
Key Sponsor Obligations Breakdown
-
Investigator and Site Selection:
- Sponsors must select investigators qualified by training and experience (evidenced by CVs, medical licenses, and past research records).
- Sponsors must ensure the site has adequate resources, facilities, equipment, and access to the target subject population.
-
Quality Management Systems (QMS):
- Sponsors must implement a system to manage quality throughout all stages of the trial, utilizing a Risk-Based Quality Management (RBQM) approach to identify critical processes and data.
-
Safety Evaluation & Expedited Reporting:
- Sponsors must conduct ongoing safety evaluations of the investigational product.
- Sponsors are legally required to report Serious Unexpected Serious Adverse Reactions (SUSARs) to regulatory authorities and all participating investigators within mandated timeframes:
- Fatal or life-threatening SUSARs: Within 7 calendar days (with a complete follow-up report within an additional 8 days).
- All other serious, unexpected ADRs: Within 15 calendar days.
-
Investigational Product Management:
- Ensuring the product is manufactured according to Good Manufacturing Practice (GMP), appropriately blinded/packaged, and supplied with instructions for handling, storage, and temperature control.
2. Investigator Responsibilities (ICH E6(R3) Annex 1 section 2 & 21 CFR 312.60 - 312.69)
The Principal Investigator (PI) is the leader and responsible party for the conduct of the trial at the trial site. If a trial is conducted by a team of individuals, the investigator is the responsible leader of the team.
Form FDA 1572: Statement of Investigator Commitments
In the United States and in global sites operating under a US Investigational New Drug (IND) application, the PI signs Form FDA 1572, legally pledging to:
- Conduct the trial in accordance with the relevant current protocol and only make changes after IRB approval (except where necessary to prevent immediate hazards).
- Personally conduct or supervise the described clinical investigation.
- Ensure that all persons assisting in the conduct of the study are informed about their obligations.
- Inform subjects that drugs are being used for investigational purposes and ensure proper informed consent (21 CFR Part 50) and IRB review (21 CFR Part 56) requirements are met.
- Report adverse experiences to the sponsor in accordance with 21 CFR 312.64.
- Maintain adequate and accurate records (source documents and CRFs) and make them available for inspection per 21 CFR 312.62.
┌───────────────────────────────────────────────────────────────────────────┐
│ CORE INVESTIGATOR RESPONSIBILITIES │
├───────────────────────────────────────────────────────────────────────────┤
│ 1. Qualifications & Agreements (current CV, medical license, GCP training)│
│ 2. Adequate Resources (sufficient time, qualified staff, eligible pool) │
│ 3. Medical Care of Participants (physician oversight, AE management) │
│ 4. Communication with IRB/IEC (initial approval, continuing reviews) │
│ 5. Compliance with Protocol (zero unauthorized deviations/amendments) │
│ 6. Investigational Product Accountability (receipt, storage, dispensing) │
│ 7. Informed Consent Process (properly timed, documented, re-consenting) │
│ 8. Accurate Source Records & CRF Completion (ALCOA+ data principles) │
│ 9. Safety Reporting (immediate 24-hour notification to sponsor for SAEs)│
└───────────────────────────────────────────────────────────────────────────┘
Sponsor vs. Investigator Responsibility Matrix
| Functional Area | Sponsor Responsibility | Investigator Responsibility |
|---|---|---|
| Protocol Design & Changes | Writes protocol; submits amendments to regulatory authorities and site PIs. | Follows protocol strictly; never implements changes without prior IRB approval unless eliminating immediate hazards. |
| IRB / Ethics Approval | Provides protocol, IB, and safety updates to sites for submission. | Submits to local/central IRB; obtains approval before screening subjects; submits annual continuing reviews. |
| Investigational Product | Manufactures per GMP; ships under cold-chain; provides Certificate of Analysis. | Maintains site accountability logs; verifies storage temperatures; dispenses only to enrolled subjects; reconciles returns. |
| Adverse Event Reporting | Evaluates cumulative safety; submits expedited SUSAR reports to regulators and all sites. | Assesses AE severity and causality; reports all Serious Adverse Events (SAEs) to sponsor within 24 hours. |
| Data Capture & Records | Provides validated EDC system; manages database; verifies source data via CRAs. | Generates accurate source documents; timely enters eCRFs; resolves data queries with supporting evidence. |
| Financial Oversight | Finances trial; collects Form FDA 1572 and Financial Disclosures (21 CFR 54). | Discloses financial interests exceeding regulatory thresholds ($25,000 equity, $25,000 significant payments). |
The Legal Reality of Non-Delegable Accountability
A critical concept on the ACRP-CP exam is that operational tasks can be delegated, but regulatory accountability cannot.
Sponsor ──(Delegates Tasks)──> CRO / Vendors ===> SPONSOR REMAINS ULTIMATELY ACCOUNTABLE
Principal Investigator ──(Delegates Tasks)──> Sub-Is / CRCs ===> PI REMAINS PERSONALLY ACCOUNTABLE
- When a Sponsor contracts a CRO to perform monitoring, data management, and medical safety review, any regulatory failure by the CRO (e.g., missed 7-day SUSAR deadlines) is legally attributed to the Sponsor.
- When a PI delegates blood draws to a research nurse or eCRF entry to a study coordinator, any non-compliance (e.g., drawing labs outside protocol visit windows, inaccurate dosing data) is cited directly against the PI on FDA Form 483 inspection observations.
Realistic Clinical Scenario: Managing Protocol Compliance Dilemmas
Scenario: Dr. Ellis is the PI on a Phase III oncology study comparing an investigational kinase inhibitor against standard chemotherapy. The protocol requires mandatory pharmacokinetic (PK) blood collection at Hour 2, Hour 4, and Hour 6 post-dose on Day 1. The clinical laboratory coordinator informs Dr. Ellis that due to staffing shortages on Friday afternoon, the Hour 6 PK draw will be missed for two subjects. The coordinator suggests having the subjects return Saturday morning (Hour 24) to draw the sample instead.
Investigator Obligation Analysis:
- Protocol Adherence: Drawing a PK sample at Hour 24 instead of Hour 6 without protocol authorization is a major protocol deviation that invalidates the drug absorption profile.
- Action Required: Dr. Ellis must not authorize an arbitrary time change. Dr. Ellis must ensure proper site staffing to meet protocol requirements, or document the missed Hour 6 sample accurately as a protocol deviation in the source document and eCRF without fabricating substitute data points.
- Corrective Action: Dr. Ellis must conduct a root cause analysis, retrain staff, and adjust scheduling procedures to prevent recurrent sample omissions.
A sponsor contracts a full-service CRO to manage all site monitoring, data management, and pharmacovigilance safety reporting for a multinational Phase III trial. During an FDA inspection of the sponsor, inspectors discover that the CRO failed to submit required 7-day fatal SUSAR reports. Who holds ultimate regulatory liability for this non-compliance?
Which of the following documents represents the legally binding agreement in the United States wherein a Principal Investigator formally pledges to personally conduct or supervise the trial and comply with all FDA regulations?
Under what circumstance may an investigator implement a deviation or change to the approved trial protocol without prior approval from the Institutional Review Board (IRB) / Independent Ethics Committee (IEC)?